Trial Profile
Phase II randomized trial of docetaxel-carboplatin in combination with iniparib (BSI-201), and docetaxel-carboplatin as neoadjuvant therapy in patients with early-stage breast cancer and triple-negative phenotype
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Iniparib (Primary) ; Carboplatin; Docetaxel
- Indications Early breast cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors Sanofi
- 09 Apr 2022 Status changed from recruiting to completed.
- 23 Jun 2011 New trial record